← Leaderboards
Martin Joseph Sadowski
New York University School Of Medicine
$14,045,716
Attributed
$14,586,113
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,586,113 · 10
By mechanism
R01$11,724,553 · 5
K08$951,240 · 2
R61$810,596 · 1
K02$648,000 · 1
P30$451,724 · 1
Top collaborators
- Paul M. Mathews1 shared
- David Minh Truong1 shared
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Michael J Garabedian$7,578,313
- Mario Delmar$22,408,317
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainS DiseaseGenesDepositionResponseAllelesKnock-OutPreventProteinsApplications GrantsApolipoprotein EAmyloid Beta-ProteinProtein IsoformsPathologyAffectPeptidesBaseIn VivoApolipoprotein E-4MediatingReceptorTransgenic MiceResistance
Grant awards (41)
Off-the-shelf CAR-Engineered Macrophage Therapy for Alzheimerâs Disease$810,596
R61 · FY2025 · AG · contact PI
Role of Microglia in Neurodegeneration -Effect of ApoE$666,923
R01 · FY2025 · AG · contact PI
Role of Microglia in Neurodegeneration -Effect of ApoE$680,533
R01 · FY2024 · AG · contact PI
Mechanisms of Peroxiredoxin 6 Endowed Protection in Alzheimerâs Disease$423,750
R01 · FY2024 · AG · contact PI
Role of Microglia in Neurodegeneration -Effect of ApoE$680,533
R01 · FY2023 · AG · contact PI
Mechanisms of Peroxiredoxin 6 Endowed Protection in Alzheimerâs Disease$423,750
R01 · FY2023 · AG · contact PI
Role of Microglia in Neurodegeneration -Effect of ApoE$725,104
R01 · FY2022 · AG · contact PI
Mechanisms of Peroxiredoxin 6 Endowed Protection in Alzheimerâs Disease$423,750
R01 · FY2022 · AG · contact PI
Mechanisms of Peroxiredoxin 6 Endowed Protection in Alzheimerâs Disease$423,750
R01 · FY2021 · AG · contact PI
Mechanisms of Peroxiredoxin 6 Endowed Protection in Alzheimerâs Disease$423,750
R01 · FY2020 · AG · contact PI
Mechanisms of Apolipoprotein E Isoform Conferred Susceptibility and Resistance to Alzheimer's Disease$422,496
R01 · FY2020 · AG · contact PI
Targeting the apoE/A-beta Interaction as a Therapeutic Approach for AD$419,783
R01 · FY2020 · AG · contact PI
Mechanisms of Apolipoprotein E Isoform Conferred Susceptibility and Resistance to Alzheimer's Disease$422,532
R01 · FY2019 · AG · contact PI
Targeting the apoE/A-beta Interaction as a Therapeutic Approach for AD$419,898
R01 · FY2019 · AG · contact PI
Mechanisms of Apolipoprotein E Isoform Conferred Susceptibility and Resistance to Alzheimer's Disease$422,568
R01 · FY2018 · AG · contact PI
Targeting the apoE/A-beta Interaction as a Therapeutic Approach for AD$420,010
R01 · FY2018 · AG · contact PI
Mechanisms of Apolipoprotein E Isoform Conferred Susceptibility and Resistance to Alzheimer's Disease$426,933
R01 · FY2017 · AG · contact PI
Targeting the apoE/A-beta Interaction as a Therapeutic Approach for AD$420,118
R01 · FY2017 · AG · contact PI
Core B. Clinical Core$451,724
P30 · FY2016 · AG · contact PI
Mechanisms of Apolipoprotein E Isoform Conferred Susceptibility and Resistance to Alzheimer's Disease$435,679
R01 · FY2016 · AG · contact PI
Targeting the apoE/A-beta Interaction as a Therapeutic Approach for AD$420,224
R01 · FY2016 · AG · contact PI
Peptoid Antagonists of the ApoE/ABeta Interaction as a Novel Anti-ABeta Therapy.$108,000
K02 · FY2014 · AG · contact PI
Targeting the apoE/ABeta Interaction as a Novel AD Therapy$135,010
R01 · FY2013 · AG · contact PI
Peptoid Antagonists of the ApoE/ABeta Interaction as a Novel Anti-ABeta Therapy$108,000
K02 · FY2013 · AG · contact PI
Targeting the apoE/ABeta Interaction as a Novel AD Therapy$327,045
R01 · FY2012 · AG · contact PI
Peptoid Antagonists of the ApoE/ABeta Interaction as a Novel Anti-ABeta Therapy$108,000
K02 · FY2012 · AG · contact PI
Targeting the apoE/ABeta Interaction as a Novel AD Therapy$381,619
R01 · FY2011 · AG · contact PI
Peptoid Antagonists of the ApoE/ABeta Interaction as a Novel Anti-ABeta Therapy$108,000
K02 · FY2011 · AG · contact PI
Therapeutic Monoclonal Antibodies for Human Prion Diseases$380,250
R01 · FY2010 · AG · contact PI
Targeting the apoE/ABeta Interaction as a Novel AD Therapy$309,600
R01 · FY2010 · AG · contact PI
Peptoid Antagonists of the ApoE/ABeta Interaction as a Novel Anti-ABeta Therapy$108,000
K02 · FY2010 · AG · contact PI
Targeting the apoE/ABeta Interaction as a Novel AD Therapy$83,512
R01 · FY2010 · AG · contact PI
Therapeutic Monoclonal Antibodies for Human Prion Diseases$380,438
R01 · FY2009 · AG · contact PI
Targeting the apoE/ABeta Interaction as a Novel AD Therapy$312,728
R01 · FY2009 · AG · contact PI
Peptoid Antagonists of the ApoE/ABeta Interaction as a Novel Anti-ABeta Therapy$108,000
K02 · FY2009 · AG · contact PI
Targeting the apoE/ABeta Interaction as a Novel AD Therapy$312,267
R01 · FY2008 · AG · contact PI
Alzheimer's therapy: Blocking ApoE/ABeta binding$208,000
K08 · FY2006 · AG · contact PI
Alzheimer's therapy: Blocking ApoE/ABeta binding$208,000
K08 · FY2005 · AG
Alzheimer's therapy: Blocking ApoE/ABeta binding$208,000
K08 · FY2004 · AG
Vaccine and Magnetic Resonance Imaging Approaches for AD$165,240
K08 · FY2003 · AG
Vaccine and Magnetic Resonance Imaging Approaches for AD$162,000
K08 · FY2002 · AG